331 related articles for article (PubMed ID: 29271504)
1. Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease.
Eddowes PJ; McDonald N; Davies N; Semple SIK; Kendall TJ; Hodson J; Newsome PN; Flintham RB; Wesolowski R; Blake L; Duarte RV; Kelly CJ; Herlihy AH; Kelly MD; Olliff SP; Hübscher SG; Fallowfield JA; Hirschfield GM
Aliment Pharmacol Ther; 2018 Mar; 47(5):631-644. PubMed ID: 29271504
[TBL] [Abstract][Full Text] [Related]
2. Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort.
Imajo K; Tetlow L; Dennis A; Shumbayawonda E; Mouchti S; Kendall TJ; Fryer E; Yamanaka S; Honda Y; Kessoku T; Ogawa Y; Yoneda M; Saito S; Kelly C; Kelly MD; Banerjee R; Nakajima A
World J Gastroenterol; 2021 Feb; 27(7):609-623. PubMed ID: 33642832
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.
Jayakumar S; Middleton MS; Lawitz EJ; Mantry PS; Caldwell SH; Arnold H; Mae Diehl A; Ghalib R; Elkhashab M; Abdelmalek MF; Kowdley KV; Stephen Djedjos C; Xu R; Han L; Mani Subramanian G; Myers RP; Goodman ZD; Afdhal NH; Charlton MR; Sirlin CB; Loomba R
J Hepatol; 2019 Jan; 70(1):133-141. PubMed ID: 30291868
[TBL] [Abstract][Full Text] [Related]
4. Multiparametric MR Index for the Diagnosis of Non-Alcoholic Steatohepatitis in Patients with Non-Alcoholic Fatty Liver Disease.
Kim JW; Lee YS; Park YS; Kim BH; Lee SY; Yeon JE; Lee CH
Sci Rep; 2020 Feb; 10(1):2671. PubMed ID: 32060386
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
Castera L; Friedrich-Rust M; Loomba R
Gastroenterology; 2019 Apr; 156(5):1264-1281.e4. PubMed ID: 30660725
[TBL] [Abstract][Full Text] [Related]
6. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.
Imajo K; Kessoku T; Honda Y; Tomeno W; Ogawa Y; Mawatari H; Fujita K; Yoneda M; Taguri M; Hyogo H; Sumida Y; Ono M; Eguchi Y; Inoue T; Yamanaka T; Wada K; Saito S; Nakajima A
Gastroenterology; 2016 Mar; 150(3):626-637.e7. PubMed ID: 26677985
[TBL] [Abstract][Full Text] [Related]
7. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease.
Costa-Silva L; Ferolla SM; Lima AS; Vidigal PVT; Ferrari TCA
Eur J Radiol; 2018 Jan; 98():82-89. PubMed ID: 29279175
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Imaging Modalities Against Liver Biopsy in Nonalcoholic Fatty Liver Disease: The Amsterdam NAFLD-NASH Cohort.
Troelstra MA; Witjes JJ; van Dijk AM; Mak AL; Gurney-Champion O; Runge JH; Zwirs D; Stols-Gonçalves D; Zwinderman AH; Ten Wolde M; Monajemi H; Ramsoekh S; Sinkus R; van Delden OM; Beuers UH; Verheij J; Nieuwdorp M; Nederveen AJ; Holleboom AG
J Magn Reson Imaging; 2021 Dec; 54(6):1937-1949. PubMed ID: 33991378
[TBL] [Abstract][Full Text] [Related]
9. Decision analytic model of the diagnostic pathways for patients with suspected non-alcoholic fatty liver disease using non-invasive transient elastography and multiparametric magnetic resonance imaging.
Blake L; Duarte RV; Cummins C
BMJ Open; 2016 Sep; 6(9):e010507. PubMed ID: 27650757
[TBL] [Abstract][Full Text] [Related]
10. Prediction of nonalcoholic fatty liver disease (NAFLD) activity score (NAS) with multiparametric hepatic magnetic resonance imaging and elastography.
Yin Z; Murphy MC; Li J; Glaser KJ; Mauer AS; Mounajjed T; Therneau TM; Liu H; Malhi H; Manduca A; Ehman RL; Yin M
Eur Radiol; 2019 Nov; 29(11):5823-5831. PubMed ID: 30887196
[TBL] [Abstract][Full Text] [Related]
11. Multiparametric MR Is a Valuable Modality for Evaluating Disease Severity of Nonalcoholic Fatty Liver Disease.
Lee YS; Yoo YJ; Jung YK; Kim JH; Seo YS; Yim HJ; Kim IH; Lee SY; Kim BH; Kim JW; Lee CH; Yeon JE; Kwon SY; Um SH; Byun KS
Clin Transl Gastroenterol; 2020 Apr; 11(4):e00157. PubMed ID: 32251018
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography.
Tapper EB; Sengupta N; Hunink MG; Afdhal NH; Lai M
Am J Gastroenterol; 2015 Sep; 110(9):1298-304. PubMed ID: 26303130
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.
Selvaraj EA; Mózes FE; Jayaswal ANA; Zafarmand MH; Vali Y; Lee JA; Levick CK; Young LAJ; Palaniyappan N; Liu CH; Aithal GP; Romero-Gómez M; Brosnan MJ; Tuthill TA; Anstee QM; Neubauer S; Harrison SA; Bossuyt PM; Pavlides M;
J Hepatol; 2021 Oct; 75(4):770-785. PubMed ID: 33991635
[TBL] [Abstract][Full Text] [Related]
14. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
[TBL] [Abstract][Full Text] [Related]
15. Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity.
Pavlides M; Banerjee R; Tunnicliffe EM; Kelly C; Collier J; Wang LM; Fleming KA; Cobbold JF; Robson MD; Neubauer S; Barnes E
Liver Int; 2017 Jul; 37(7):1065-1073. PubMed ID: 27778429
[TBL] [Abstract][Full Text] [Related]
16. Imaging biomarkers of NAFLD, NASH, and fibrosis.
Ajmera V; Loomba R
Mol Metab; 2021 Aug; 50():101167. PubMed ID: 33460786
[TBL] [Abstract][Full Text] [Related]
17. Modelling the cost effectiveness of non-alcoholic fatty liver disease risk stratification strategies in the community setting.
Congly SE; Shaheen AA; Swain MG
PLoS One; 2021; 16(5):e0251741. PubMed ID: 34019560
[TBL] [Abstract][Full Text] [Related]
18. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD.
Boursier J; Guillaume M; Leroy V; Irlès M; Roux M; Lannes A; Foucher J; Zuberbuhler F; Delabaudière C; Barthelon J; Michalak S; Hiriart JB; Peron JM; Gerster T; Le Bail B; Riou J; Hunault G; Merrouche W; Oberti F; Pelade L; Fouchard I; Bureau C; Calès P; de Ledinghen V
J Hepatol; 2019 Aug; 71(2):389-396. PubMed ID: 31102719
[TBL] [Abstract][Full Text] [Related]
19. Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease.
Younossi ZM; Felix S; Jeffers T; Younossi E; Nader F; Pham H; Afendy A; Cable R; Racila A; Younoszai Z; Lam BP; Golabi P; Henry L; Stepanova M
JAMA Netw Open; 2021 Sep; 4(9):e2123923. PubMed ID: 34529067
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
